Lv1
20 积分 2025-08-06 加入
Identifying immunohistochemical biomarkers panel for non-small cell lung cancer in optimizing treatment and forecasting efficacy
8个月前
已关闭
PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial
8个月前
已完结
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial
8个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
8个月前
已完结
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
8个月前
已完结
15P Furmonertinib combined with anlotinib as the first-line treatment in patients with EGFR exon 21 Leu858Arg mutation: Results from FOCUS-A study
8个月前
已完结
15P Furmonertinib combined with anlotinib as the first-line treatment in patients with EGFR exon 21 Leu858Arg mutation: Results from FOCUS-A study
8个月前
已完结
75P: Firmonertinib plus anlotinib for first-line treatment of advanced EGFR L858R mutated non-small cell lung cancer
8个月前
已关闭
Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
8个月前
已完结
Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study
8个月前
已完结
皖公网安备34019202002308
